Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

孟得新 - NMPA Drug Approval Details

Approvals/NMPA/Cefamandole Nafate for Injection

Approved

化学药品

Cefamandole Nafate for Injection

Unknown🇨🇳 National Medical Products Administration

Approval Date: Nov 5, 2020
Approval ID: 888G2W4V8Tf
Company: Unknown
Type: 化学药品

Approval Details

Approval Id: 888G2W4V8Tf
Approval Number: 国药准字HC20150034
Generic Name: 注射用头孢孟多酯钠
Generic Name En: Cefamandole Nafate for Injection
Trade Name: 孟得新
Brand Name: 孟得新
Drug Type: 化学药品
Dosage Form: 注射剂
Strength: 1.0g(按C18H18N6O5S2计算)
Reg Date: 2020-11-05
Expired Date: 2025-11-04
Production Company Address: 台南市新营区土库里土库六之二十号

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Nov 5, 2020

Approval ID

888G2W4V8Tf

Type

化学药品

Back to NMPA Approvals